The purpose of this study is to learn more about how metastatic breast cancer changes over time and how those changes may affect which treatments work best. By studying tumor tissue and blood samples, researchers hope to identify specific features, called biomarkers, that can help match each person to the treatment that's most likely to help them. This information may also help doctors better understand why some cancers respond to treatment and others do not, so that future patients can receive more personalized care.

The purpose of this research study is to create a Lymphoma Registry of patients who are willing to complete the study's comprehensive assessment. The assessment is designed to gather information on memory, nutritional status, mental health, and level social support. It is also designed to understand how well you carry out your day to day activities and to briefly describe what other medical conditions you may have. This assessment will help your health care team determine your "functional age" (the age you function at) as compared to how many years old you are. We will also ask you to complete questionnaires that ask questions about your personal health history, such as exercise and smoking,

The purpose of this study is to explore etentamig (ABBV-383) and its safety and tolerability as a monotherapy or combined with other anti-myeloma agents. This study aims to determine the safest dose of etentamig and if it produces meaningful anti-myeloma activity for participant with multiple myeloma (MM).

This study is being conduced to assess the feasibility of conducting multi-center prospective studies on surgical excision of suspected OSSN lesions in SSA in people living with HIV/AIDS (PLWHA).

The purpose of this single-arm phase 2 study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.

The purpose of this protocol addendum is to provide participants from Study LOXO-NGR-21001 (J3T-OX-JZTA), who continue to receive benefit from LOXO-260, the opportunity for continued access to LOXO-260.

The purpose of this research is to see if a radioactive tracer called (21-[18F]fluoro-16α,17α-[(R)-1'-α- furylmethylidene)dioxyl]-19-norpregn-4-ene-3,20 dione) (also referred to as 18F-FFNP) with positron emission tomography (PET) scanning can provide more information about your response to endocrine therapy when it is combined with Abemaciclib, a member of the class of medications known as CDK4/CDK6 inhibitors.

To gather information on the technique of staging laparoscopy and processing of peritoneal washings through a survey of practicing surgical oncologists. This presents an opportunity to potentially standardize this procedure in future. This may help facilitate more accurate staging of the peritoneum.

This study is looking at how platelets-blood cells that help stop bleeding-are collected, processed, and used for cancer patients in Malawi. Right now, platelet supplies are limited, and some transfusions are delayed or not completed. We want to understand what happens at each step, from the blood donors who give blood, to the Malawi Blood Transfusion Service where platelets are prepared, to the hospitals where patients receive them. By reviewing donor and lab records, tracking transfusions, and talking with doctors, nurses, and lab staff, we hope to find simple, realistic ways to improve the process. The goal is to make platelet transfusions safer, faster, and more reliable for patients who need them most.

The purpose of this study is to determine if treating germinomas with chemotherapy followed by a lower dose of radiotherapy (RT) can be as effective as the current standard of care. Specifically, our primary aim is to determine whether 12 Gy whole ventricular irradiation (WVI) and 12 Gy tumor boost would maintain similar efficacy compared to ACNS1123 stratum 2 as measured by event-free survival (EFS) in eligible patients with localized primary central nervous system (CNS) germinoma who present with serum and/or CSF human chorionic gonadotropin-beta (hCGß) = 100 IU/L and normal AFP, and meet complete response (CR) or continued complete response (CCR) criteria following chemotherapy/second-look surgery (Stratum 1). We are attempting to build upon the excellent results of ACNS1123 stratum 2 by reducing the RT dose even further for patients in a CR after chemotherapy.